Dr Batlevi Shares Promising Data of Tazemetostat from SYMPHONY-1 Trial

from Oncology Learning Network · host HMP Global

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Episode metadata supplied by the publisher feed · Published Mar 21, 2022

Embed this episode

Attribution link and audio player

Ready to play

Dr Batlevi Shares Promising Data of Tazemetostat from SYMPHONY-1 Trial

0:00 4:46

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 4 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on March 21, 2022.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!